Showing results (81-90 of 99) with videos related to
Sort By:
Pageof 10
Genes and Immunity|July 11, 2008
HLA-DRB1*15 allele influences the later course of relapsing remitting multiple sclerosisI Cournu-Rebeix, E Génin, E Leray, et al.Journal of Neuroimmunology|January 8, 2000
Cytokines in genetic susceptibility to multiple sclerosis: a candidate gene approach. French Multiple Sclerosis Genetics GroupJ Reboul, C Mertens, F Levillayer, et al.European Journal of Neurology|February 6, 2013
A web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosisI Galea, C Lederer, A Neuhaus, et al.Neurology|August 19, 2011
Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndromeH-P Hartung, M S Freedman, C H Polman, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|December 21, 2011
Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysisM S Freedman, C Metzig, L Kappos, et al.Journal of Neurology|September 9, 2020
SMILE: a predictive model for Scoring the severity of relapses in MultIple scLErosisF Lejeune, A Chatton, D-A Laplaud, et al.Neurology|September 25, 1998
A systematic study of oligodendrocyte growth factors as candidates for genetic susceptibility to MS. French Multiple Sclerosis Genetics GroupC Mertens, D Brassat, J Reboul, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|November 7, 2008
The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosisN De Stefano, M Filippi, C Confavreux, et al.Journal of Neurology, Neurosurgery, and Psychiatry|February 1, 1997
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteriaG Edan, D Miller, M Clanet, et al.Neurology|April 13, 2005
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severityR H S R Roxburgh, S R Seaman, T Masterman, et al.Pageof 10